The US Food and Drug Administration has issued new labeling changes for all approved testosterone replacement therapy ...

About Marius Pharmaceuticals ... or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare ...

The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

Its growth is driven by a rising awareness of hypogonadism. The global testosterone replacement therapy (TRT) market is projected to grow by $461m by 2029 at a compound annual growth rate of 3.3% ...

The new Marius Pharmaceuticals website offers valuable resources on testosterone deficiency as a widespread health concern, emphasizing its impact beyond traditional perceptions. Recognizing the broad ...

In September 2024, Marius Pharmaceuticals proactively submitted ... has reaffirmed the safety and benefits of testosterone therapy. A global consensus has emerged on testosterone’s ...

RALEIGH, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals ... hypogonadism or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and mitigate ...